title: Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus.
abstract: Among approximately 1000 adenoviruses from chimpanzees and bonobos studied recently, the Pan Adenovirus type 3 (PanAd3, isolated from a bonobo, Pan paniscus) has one of the best profiles for a vaccine vector, combining potent transgene immunogenicity with minimal pre-existing immunity in the human population. In this study, we inserted into a replication defective PanAd3 a transgene expressing a fusion protein of conserved influenza antigens nucleoprotein (NP) and matrix 1 (M1). We then studied antibody and T cell responses as well as protection from challenge infection in a mouse model. A single intranasal administration of PanAd3-NPM1 vaccine induced strong antibody and T cell responses, and protected against high dose lethal influenza virus challenge. Thus PanAd3 is a promising candidate vector for vaccines, including universal influenza vaccines.
authors.affiliation: Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration,Bethesda, Maryland, United States of America.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Vitelli
authors.forename: Mary R
authors.initials: MR
authors.lastname: Quirion
authors.forename: Chia-Yun
authors.initials: CY
authors.lastname: Lo
authors.forename: Julia A
authors.initials: JA
authors.lastname: Misplon
authors.forename: Agnieszka K
authors.initials: AK
authors.lastname: Grabowska
authors.forename: Angiolo
authors.initials: A
authors.lastname: Pierantoni
authors.forename: Virginia
authors.initials: V
authors.lastname: Ammendola
authors.forename: Graeme E
authors.initials: GE
authors.lastname: Price
authors.forename: Mark R
authors.initials: MR
authors.lastname: Soboleski
authors.forename: Riccardo
authors.initials: R
authors.lastname: Cortese
authors.forename: Stefano
authors.initials: S
authors.lastname: Colloca
authors.forename: Alfredo
authors.initials: A
authors.lastname: Nicosia
authors.forename: Suzanne L
authors.initials: SL
authors.lastname: Epstein
mesh_terms: D000260:Adenoviruses, Human / Q000276:immunology; D000261:Adenoviruses, Simian / Q000235:genetics / Q000276:immunology*; D000595:Amino Acid Sequence; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D003429:Cross Reactions / Q000276:immunology; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal; D053118:Influenza A Virus, H1N1 Subtype / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008969:Molecular Sequence Data; D019590:Nucleocapsid Proteins; D000090243:Nucleophosmin; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*; D019974:Pan paniscus; D016601:RNA-Binding Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014758:Viral Core Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D014763:Viral Matrix Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D007252:Influenza Vaccines; C488936:M1 protein, Influenza A virus; C048842:NP protein, Influenza A virus; C000716967:NPM1 protein, human; C000715570:Npm1 protein, mouse; D019590:Nucleocapsid Proteins; D016601:RNA-Binding Proteins; D011993:Recombinant Fusion Proteins; D014758:Viral Core Proteins; D014763:Viral Matrix Proteins; D000090243:Nucleophosmin
references.citation: Gene Ther. 2004 Mar;11(5):431-8
references.pmid: 14973536
references.citation: J Pharm Sci. 2004 Oct;93(10):2458-75
references.pmid: 15349956
references.citation: Sci Transl Med. 2012 Jan 4;4(115):115ra2
references.pmid: 22218691
references.citation: J Virol. 2011 May;85(10):5027-35
references.pmid: 21367900
references.citation: J Gen Virol. 1977 Jul;36(1):59-74
references.pmid: 886304
references.citation: J Clin Invest. 2008 Oct;118(10):3478-90
references.pmid: 18802496
references.citation: Virology. 1995 Oct 20;213(1):131-9
references.pmid: 7483256
references.citation: J Virol. 2004 Mar;78(6):2666-73
references.pmid: 14990686
references.citation: Hum Gene Ther. 2006 May;17(5):500-6
references.pmid: 16716107
references.citation: J Virol. 2000 Jan;74(1):505-12
references.pmid: 10590140
references.citation: Virology. 2006 Mar 15;346(2):394-401
references.pmid: 16356525
references.citation: J Virol. 2005 May;79(10):6516-22
references.pmid: 15858035
references.citation: J Virol. 1996 Nov;70(11):7498-509
references.pmid: 8892868
references.citation: Vaccine. 2009 Nov 5;27(47):6512-21
references.pmid: 19729082
references.citation: Cell. 1984 Nov;39(1):13-25
references.pmid: 6091906
references.citation: J Virol. 2007 May;81(9):4654-63
references.pmid: 17329340
references.citation: J Virol. 1994 Jan;68(1):530-4
references.pmid: 8254767
references.citation: Gene Ther. 2006 Mar;13(5):421-9
references.pmid: 16319951
references.citation: J Gen Virol. 1999 Feb;80 ( Pt 2):345-353
references.pmid: 10073694
references.citation: J Immunol. 2011 Apr 1;186(7):4331-9
references.pmid: 21357542
references.citation: J Immunol. 2000 Mar 15;164(6):3274-82
references.pmid: 10706720
references.citation: Vaccine. 2005 Nov 16;23(46-47):5404-10
references.pmid: 16011865
references.citation: Virology. 1996 May 1;219(1):220-7
references.pmid: 8623532
references.citation: PLoS One. 2010 Oct 04;5(10):e13162
references.pmid: 20976273
references.citation: Vaccine. 2003 May 1;21(16):1776-9
references.pmid: 12686093
references.citation: J Immunol. 2001 Jun 15;166(12):7437-45
references.pmid: 11390496
references.citation: Vaccine. 2009 Jun 2;27(27):3501-4
references.pmid: 19464527
references.citation: J Immunol. 2004 Feb 15;172(4):2453-60
references.pmid: 14764717
references.citation: Hum Gene Ther. 2004 Mar;15(3):293-304
references.pmid: 15018738
references.citation: Virology. 1997 Mar 31;230(1):62-71
references.pmid: 9126262
references.citation: J Immunol. 1997 Feb 15;158(4):1507-15
references.pmid: 9029084
references.citation: Expert Rev Vaccines. 2010 Nov;9(11):1325-41
references.pmid: 21087110
references.citation: Hum Gene Ther. 2004 May;15(5):519-30
references.pmid: 15144581
references.citation: J Exp Med. 1987 Feb 1;165(2):408-16
references.pmid: 3029268
references.citation: Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785-9
references.pmid: 3872457
references.citation: J Exp Med. 1997 Dec 15;186(12):2063-8
references.pmid: 9396777
references.citation: Vaccine. 2009 Feb 25;27(9):1293-300
references.pmid: 19162112
references.citation: J Gen Virol. 1989 Aug;70 ( Pt 8):2111-9
references.pmid: 2769232
references.citation: J Virol. 2006 Dec;80(24):12009-16
references.pmid: 17035318
references.citation: Int Immunol. 2000 Jan;12(1):91-101
references.pmid: 10607754
references.citation: Eur J Immunol. 2008 Mar;38(3):732-41
references.pmid: 18266272
references.citation: J Virol. 1998 Jul;72(7):5648-53
references.pmid: 9621023
references.citation: Gene Ther. 2004 May;11(9):791-6
references.pmid: 14961070
references.citation: J Immunol. 2008 Sep 15;181(6):4168-76
references.pmid: 18768874
references.citation: J Exp Med. 2010 Jun 7;207(6):1153-60
references.pmid: 20457758
references.citation: Emerg Infect Dis. 2007 Mar;13(3):426-35
references.pmid: 17552096